Brokerages forecast that Mersana Therapeutics Inc (NASDAQ:MRSN) will announce ($0.60) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Mersana Therapeutics’ earnings, with estimates ranging from ($0.63) to ($0.56). Mersana Therapeutics posted earnings per share of ($0.35) in the same quarter last year, which would suggest a negative year over year growth rate of 71.4%. The company is scheduled to issue its next earnings report on Thursday, November 8th.

According to Zacks, analysts expect that Mersana Therapeutics will report full year earnings of ($2.32) per share for the current financial year, with EPS estimates ranging from ($2.43) to ($2.21). For the next fiscal year, analysts forecast that the business will post earnings of ($2.21) per share, with EPS estimates ranging from ($2.55) to ($1.86). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Mersana Therapeutics.

Mersana Therapeutics (NASDAQ:MRSN) last announced its earnings results on Wednesday, August 15th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.04. The business had revenue of $4.19 million for the quarter, compared to the consensus estimate of $3.74 million. Mersana Therapeutics had a negative return on equity of 72.63% and a negative net margin of 276.81%.

Several research firms have issued reports on MRSN. Zacks Investment Research downgraded Mersana Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 10th. ValuEngine upgraded Mersana Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, June 29th. HC Wainwright set a $33.00 price objective on Mersana Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 6th. Robert W. Baird set a $20.00 price objective on Mersana Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 15th. Finally, Leerink Swann downgraded Mersana Therapeutics from an “outperform” rating to a “market perform” rating and set a $61.00 price objective on the stock. in a report on Thursday, July 19th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $29.00.

MRSN stock traded down $3.24 during midday trading on Monday, hitting $11.14. 921,200 shares of the company’s stock were exchanged, compared to its average volume of 145,736. Mersana Therapeutics has a 12-month low of $8.76 and a 12-month high of $23.96. The company has a market capitalization of $329.47 million, a PE ratio of -3.24 and a beta of -1.82.

In other Mersana Therapeutics news, insider Timothy B. Lowinger sold 3,500 shares of Mersana Therapeutics stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $13.15, for a total transaction of $46,025.00. The transaction was disclosed in a filing with the SEC, which is available through this link. 39.70% of the stock is owned by insiders.

Hedge funds have recently bought and sold shares of the business. BlackRock Inc. grew its position in shares of Mersana Therapeutics by 41.7% in the 1st quarter. BlackRock Inc. now owns 818,004 shares of the company’s stock worth $12,899,000 after acquiring an additional 240,705 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Mersana Therapeutics in the 1st quarter worth approximately $2,681,000. Millennium Management LLC acquired a new position in shares of Mersana Therapeutics in the 2nd quarter worth approximately $2,198,000. Northern Trust Corp grew its position in shares of Mersana Therapeutics by 111.0% in the 1st quarter. Northern Trust Corp now owns 111,669 shares of the company’s stock worth $1,761,000 after acquiring an additional 58,743 shares in the last quarter. Finally, American Century Companies Inc. acquired a new position in shares of Mersana Therapeutics in the 2nd quarter worth approximately $776,000. Institutional investors own 82.61% of the company’s stock.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability.

Featured Article: Trading Strategy Methods and Types

Get a free copy of the Zacks research report on Mersana Therapeutics (MRSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.